Cost-Effectiveness of Teduglutide for Pediatric Patients with Short Bowel Syndrome in Japan, Including Caregiver Burden
Incorporating the caregiver's burden in the cost-effectiveness analysis of teduglutide for pediatric patients with SBS provided a more comprehensive assessment of the value of teduglutide for patients, their families, and society. This approach enhances our understanding of the overall value of a treatment, especially for diseases with significant caregiver burden.
Authors
- Hisato Deguchi (ORCID: https://orcid.org/0000-0001-7797-1030)
- Masafumi Kato (ORCID: https://orcid.org/0000-0002-3813-1220)
Institutions
- Takeda (Japan) (JP)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1007/s12325-024-02995-7
- Primary Topic
- Clinical Nutrition and Gastroenterology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Takeda Pharmaceutical Company